PathAI

What it does

PathAI is an AI-native digital pathology company - providing AI-powered tools for pathologists to analyze whole slide images (WSIs) for disease diagnosis and for pharmaceutical companies to develop companion diagnostics and run clinical trials. AI capabilities include deep learning tissue analysis that identifies and quantifies cellular structures, tumor regions, and biomarker expression from digitized pathology slides, AI pathology quality control that flags technical slide preparation errors before diagnosis, companion diagnostic development that creates AI-based biomarkers for patient stratification in clinical trials, computational pathology models that quantify complex tissue characteristics that pathologists estimate subjectively, and AI-assisted diagnosis that provides pathologists with quantitative measurements supporting more reproducible diagnoses.

Strengths

• Large pharmaceutical companies use PathAI for companion diagnostic development - AI biomarker models enabling patient stratification in oncology clinical trials. Large health systems use PathAI for AI-assisted pathology diagnosis with quantitative tissue analysis.
• PathAI is an AI-native digital pathology company - providing AI-powered tools for pathologists to analyze whole slide images (WSIs) for disease diagnosis and for pharmaceutical companies to develop companion diagnostics and run clinical trials.
• AI capabilities include deep learning tissue analysis that identifies and quantifies cellular structures, tumor regions, and biomarker expression from digitized pathology slides, AI pathology quality control that flags technical slide preparation errors before diagnosis, companion diagnostic development that creates AI-based biomarkers for patient stratification in clinical trials, computational pathology models that quantify complex tissue characteristics that pathologists estimate subjectively, and AI-assisted diagnosis that provides pathologists with quantitative measurements supporting more reproducible diagnoses.

Watch-outs

• Requires digital pathology whole slide imaging infrastructure: PathAI's AI operates on digitized whole slide images — pathology labs still using glass slide review need to invest in scanning infrastructure before AI-assisted digital pathology is applicable.
• Regulatory clearance varies by indication and geography: AI pathology tools require FDA clearance or CE marking for clinical use — PathAI models have different regulatory status by indication and geography, which buyers must verify for their specific clinical use case.
• Competes with Paige.AI and Visiopharm for computational pathology: Paige.AI and Visiopharm offer competing AI pathology platforms — pharmaceutical and health system buyers should evaluate AI model accuracy, regulatory status, and workflow integration across these vendors.

Pricing

PathAI enterprise contracts through pharmaceutical and health system partnerships. Not published. Annual contracts.